Stayble Therapeutics AB is a clinical stage pharmaceutical company focused on developing STA363, an intradiscally injected formulation to address chronic discogenic low back pain. The treatment targets patients whose back pain persists after physiotherapy and analgesics. With a one-time injection, STA363 aims to correct the underlying causes of disc-related low back pain by addressing disc instability and preventing the leakage of inflammatory mediators. Stayble's vision is to make STA363 the new standard treatment for patients suffering from this debilitating condition, offering long-lasting pain relief with minimal rehabilitation. The company's experienced team, including a renowned back-pain researcher and bio-entrepreneurs, is dedicated to bringing this innovative solution to millions of disabled patients.